Another pharmaceutical stock is advancing into the "A+H" era!

Since the opening of the science and technology innovation board, the number of "A + H" shares has continued to grow, and from the previous pharmaceutical companies such as Baiyun Mountain and Shanghai Pharmaceutical, it has changed into a research and development pharmaceutical company represented by WuXi AppTec and CanSino, and then to some unprofitable innovative drug companies
.

On September 21, the official listing of the Innocent Healthcare Science and Technology Innovation Board means that the stock has entered the "A+H" era, and Innocent HealthCare has also become the fifth unprofitable innovative drug company
listed on the "A+H".

The company's IPO raised 4 billion yuan, and the funds raised will be used for new drug research and development projects, drug research and development platform upgrade projects, marketing network construction projects, information construction projects and supplementary working capital
.

On 23 March 2020, Noble Healthview was listed on the Hong Kong Stock Exchange and raised HK$
2.
576 billion.

In December of the same year, Nova's first product, the oral BTK inhibitor obutinib, was marketed for the treatment of recurrent or refractory CLL/SLL and relapsed or refractory MCL
.

Previously, ibretinib and zebutinib were approved for listing
in China in August 2017 and June 2020, respectively.

According to Frost & Sullivan analysis, the global BTK inhibitor market has increased to $7.
2 billion in 2020 and is expected to reach $20 billion by 2025 at a compound annual growth rate of 22.
7%, while the Chinese market has also grown rapidly since the approval of ibratinib in 2017, reaching 1.
3 billion yuan in 2020, which is expected to be 58.
6%.
of the compound annual growth rate will grow to $13.
1 billion in 2025.
As a competitor in the domestic BTK inhibitor market, Nuocheng Jianhua actively strives to stand out on the track, and obrotinib has been included in the 2021 medical insurance directory and has been released from this year
.

In 2021, obutinib contributed 241 million yuan
in sales.

According to the 2022 semi-annual report, the total revenue of Nuocheng Jianhua in the first half of 2022 was 246 million yuan, up 142% year-on-year, of which the sales volume of obufixib after it was included in medical insurance increased by 115%
year-on-year.

In addition, obutinib has also been included in the "dual-channel" mechanism, or will benefit
further.

While the domestic layout is in full swing, Nuocheng Jianhua has also accelerated the pace
of international expansion.

In June 2021, obulatinib received FDA-granted orphan drug certification and breakthrough therapy recognition for relapsed or refractory MCL by
the FDA.

It is reported that the company will further plan clinical trials for other B-cell lymphomas in the United States, and will further share the global BTK inhibitor market
.

It is worth mentioning that the research and development of innovative drugs has the characteristics of large R&D investment, and Nuocheng Jianhua, as an unprofitable innovative drug company, continues to increase R&D investment in R&D investment
.

According to the prospectus, from 2019 to 2021, the R&D investment of Nuocheng Jianhua was 234 million yuan, 423 million yuan and 733 million yuan respectively, with a compound increase of 2.
13 times in
two years.

In the first half of 2022, R&D investment was 278 million yuan, an increase of 45.
59%
year-on-year.

Under the continuous investment in R & D, the company's R & D pipeline continues to advance, as of now, in addition to obutrinib, Tafasitamab has been approved in Boao Super Hospital as a clinically urgent need for imported drugs, and another 12 products are in the I/II/III clinical trial stage, 4 products are in the preclinical stage
.

Among them, Tafasitamab is a monoclonal antibody targeting CD19, which was acquired by Nuocheng Jianhua from Incyte in August 2021 for the development and exclusive commercialization rights
of Tafasitamab in the field of hematological and solid tumors in Greater China (Chinese mainland, Hong Kong, Macau and Taiwan).

As of December 31, 2021, only two CD19-targeting monoclonal antibodies have been approved for marketing worldwide, Inebilizumab and Tafasitamab, and no CD19-targeting monoclonal antibodies have been approved for marketing
in China.

The industry believes that the Tafasitamab of Nuocheng Jianhua is expected to become the first CD19 monoclonal antibody in China
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.